Prognostic Value of Baseline Medications Plus Neutrophil-to-Lymphocyte Ratio in the Effectiveness of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer: A Retrospective Study

BACKGROUND: Nivolumab and pembrolizumab are the standard treatments for patients with advanced non-small-cell lung cancer (NSCLC). While there are reports on several inflammatory indices and the prognosis of patients with cancer, no study has combined baseline medication with the neutrophil-to-lymph...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogiwara, Toshiki, Kawazoe, Hitoshi, Egami, Saeka, Hashimoto, Hironobu, Saito, Yoshimasa, Sakiyama, Naomi, Ohe, Yuichiro, Yamaguchi, Masakazu, Furukawa, Tetsuya, Hara, Azusa, Hiraga, Yui, Jibiki, Aya, Yokoyama, Yuta, Suzuki, Sayo, Nakamura, Tomonori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606521/
https://www.ncbi.nlm.nih.gov/pubmed/34820333
http://dx.doi.org/10.3389/fonc.2021.770268

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606521/
https://www.ncbi.nlm.nih.gov/pubmed/34820333
http://dx.doi.org/10.3389/fonc.2021.770268

Ejemplares similares